Insider Selling: Repligen (NASDAQ:RGEN) Director Sells $3,092,200.00 in Stock

Repligen Corporation (NASDAQ:RGEN) Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the sale, the director directly owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This represents a 19.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Anthony Hunt also recently made the following trade(s):

• On Wednesday, November 12th, Anthony Hunt sold 25,000 shares of Repligen stock. The shares were sold at an average price of $156.88, for a total transaction of $3,922,000.00.

Repligen Trading Up 1.2%

RGEN opened at $152.37 on Monday. The firm has a 50 day simple moving average of $141.04 and a 200 day simple moving average of $129.65. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a market cap of $8.58 billion, a price-to-earnings ratio of 7,622.31, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after acquiring an additional 430,039 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company’s stock worth $130,317,000 after purchasing an additional 13,284 shares in the last quarter. Brown Capital Management LLC grew its position in Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock valued at $125,036,000 after purchasing an additional 141,241 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Repligen by 4.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock valued at $106,826,000 after buying an additional 31,505 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in Repligen by 390.6% during the 3rd quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock worth $102,557,000 after buying an additional 610,837 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on RGEN shares. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price for the company in a research note on Tuesday, July 22nd. HSBC assumed coverage on shares of Repligen in a research report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective for the company. Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Repligen in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.